---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-26-000027"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2026-05-07T23:59:59+00:00"
generated_at: "2026-05-14T22:02:16.816846+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Xeris Biopharma Q1 revenue up 43% to $82M; Recorlev nearly doubles to $50M; raises FY guidance to $380-390M

## Summary
- Product revenue $82.5M, up 43% YoY; total revenue $83.1M, up 38%. Net income $2.2M vs net loss $9.2M.
- Recorlev net revenue $49.8M, up 95% driven by patient demand; Gvoke flat at $20.8M; Keveyis $11.9M, up 4%.
- Adjusted EBITDA $15.1M, improvement of $10.7M YoY; gross margin improved to 87% from 85%.
- Raises FY2026 total revenue guidance; tightens range to $380-390M (>30% growth at midpoint).
- Plans Phase 3 initiation of XP-8121 later in 2026; commercial team expansion completed.

## SEC filing metadata
- accession: 0001867096-26-000027
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2026-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000027/0001867096-26-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000027/xers-20260507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-26-000027
- JSON: https://secwatch.observer/filing/0001867096-26-000027.json
- Plain text: https://secwatch.observer/filing/0001867096-26-000027.txt

## Source-grounded claims
- claim_id: d8828185fb00466c251333fa463fffd04c7f4039
  claim: Xeris Biopharma Holdings, Inc. reported the three months ended March 31, 2026 results: revenue $83,127, net income $2.2 million.
  evidence_excerpt: Three months ended March 31, Change 2026 2025 $ % Product revenue (in thousands): Recorlev $ 49,768 $ 25,530 $ 24,238 95 Gvoke 20,800 20,845 (45) — Keveyis 11,886 11,427 459 4 Product revenue, net 82,454 57,802 24,652 43 Royalty, contract and other revenue 673 2,317 (1,644) (71) Total revenue $ 83,127 $ 60,119 $ 23,008 38
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709626000027/0001867096-26-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.